[Oral TRH stimulation in patients with thyroid carcinoma].
In patients with differentiated thyroid carcinoma high serum TSH-levels enhance 131 J-uptake in thyroid remnant and/or metastases. An effective increase of TSH could be achieved by oral administration of thyrotropin releasing hormone (TRH) even after a short T4/T3-withdrawal period so that we recommend a TRH-stimulation in all patients before a diagnostic or therapeutic 131 J-application. Adverse reactions to TRH are infrequent and usually short timed so that in contrast to TSH-stimulation--TRH can be given to outpatients without any risk.
D000284:Administration, Oral; D000328:Adult; D006801:Humans; D007457:Iodine Radioisotopes; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011877:Radionuclide Imaging; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging; D013972:Thyrotropin / Q000008:administration & dosage / Q000097:blood; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects
D007457:Iodine Radioisotopes; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin
Orale TRH-Stimulation bei Schilddrüsenkarzinompatienten.